Eladio Carrera, MD
Gastroenterology · Las Vegas, NVNPI 1508967605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 27.8% of the total. 2025 is the largest year on record at $2,820, 2.8 times the $1,025 reported in 2019.
Across 433 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- QOL Medical, LLC$1K
- Johnson & Johnson$1K
- Sanofi$794
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$720
- Takeda Pharmaceuticals U.S.A., Inc.$577
- plus $5K from 27 others
What the payments were for
- Speaking & faculty fees$4003%
- Food & beverage$12,25693%
- Education$2162%
- Gifts$2422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $3,652 |
| QOL Medical, LLC | 34 | $1,169 |
| Johnson & Johnson(2 entities) | 54 | $1,148 |
| Sanofi | 31 | $794 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $720 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $577 |
| Ardelyx, Inc. | 18 | $523 |
| Regeneron Healthcare Solutions, Inc. | 6 | $418 |
| Braintree Laboratories, Inc. | 17 | $346 |
| Aimmune Therapeutics, Inc. | 13 | $346 |
| Nestle Healthcare Nutrition Inc. | 9 | $323 |
| Pfizer | 3 | $297 |
| Redhill Biopharma Inc. | 12 | $287 |
| Madrigal Pharmaceuticals | 2 | $287 |
| Merck | 16 | $268 |
| Gilead | 12 | $267 |
| Ironwood Pharmaceuticals, Inc | 7 | $263 |
| Celltrion USA Inc. | 7 | $213 |
| Enterra Medical, Inc. | 1 | $166 |
| AstraZeneca | 2 | $155 |
| Lilly USA, LLC | 2 | $149 |
| Phathom Pharmaceuticals, Inc. | 2 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $131 |
| Esperion Therapeutics, Inc. | 1 | $130 |
| Organon | 3 | $64 |
| Ferring Pharmaceuticals Inc. | 3 | $50 |
| Intercept Pharmaceuticals, Inc. | 2 | $48 |
| Orphalan Inc | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Intra-sana Laboratories | 2 | $30 |
| GSK | 1 | $26 |
| Boston Scientific | 1 | $23 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,114 in reported general payments places this provider in the 85th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 65 | $57,827 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 142 | $2,045 |
| Pantoprazole Sodium | 257 | $1,589 |
| Famotidine | 175 | $1,358 |
| Budesonide DrBudesonide | 12 | $1,275 |
| Clotrimazole | 22 | $803 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 42 | $728 |
| Ondansetron OdtOndansetron | 24 | $581 |
| Rabeprazole Sodium | 15 | $514 |
| LoperamideLoperamide Hcl | 16 | $477 |
| Omeprazole | 89 | $404 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $321 |
| Clarithromycin | 13 | $256 |
| Amoxicillin | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $3,652 | $57,82765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- Christian StoneLas Vegas$1.1M
- James HanLas Vegas$47K
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Tarek AmmarLas Vegas$14K
- Uday SaraiyaLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.